Medical College of Wisconsin, 8701 W. Watertown Plank Rd, Milwaukee, WI, 53226, USA.
Concordia University of Wisconsin, School of Pharmacy, 12800 N Lake Shore Dr, Mequon, WI, 53097, USA.
J Med Toxicol. 2019 Oct;15(4):271-275. doi: 10.1007/s13181-019-00717-y. Epub 2019 Jul 8.
Lacosamide (Vimpat®) is an anticonvulsant used to treat partial-onset seizures. Little is known about the characteristics and outcomes of patients exposed to lacosamide.
To characterize lacosamide exposures reported to US poison centers with regard to patient demographics, clinical effects, and outcomes.
This retrospective observational study queried the National Poison Data System (NPDS) for single substance lacosamide exposures from January 2008 to December 2016. Variables of interest included age, gender, medical outcome, management site, level of healthcare facility, reason for exposure, and clinical effects.
Lacosamide exposures were identified in 1124 patients, ranging from ages 2 months to 99 years. Six hundred and twenty-two patients (55.3%) were female. Nine hundred and seventy-six patients (86.8%) had minimal or no toxic effects. Life-threatening exposures numbered 30 cases (2.7%). There was one death. Five hundred and forty-eight patients (48.8%) did not require healthcare management while 537 (47.7%) were either referred to or already at a hospital. Among those treated at a healthcare facility, 269 (50.1%) did not require admission. Thirty-three patients (6.1%) were admitted to a psychiatric facility, 68 (12.7%) to a non-critical care unit, and 93 (17.3%) to a critical care unit. Six hundred and thirty-two exposures (56.2%) were due to therapeutic error. Suicide attempts numbered 168 (14.9%). Neurologic, gastrointestinal, and cardiovascular symptoms were commonly encountered.
Lacosamide exposures infrequently cause death or disability; however, a considerable proportion of the study population required intensive care. Exposed patients with symptoms require healthcare evaluation.
拉科酰胺（Vimpat®）是一种抗癫痫药，用于治疗部分发作性癫痫。目前对于接触拉科酰胺的患者的特征和结局知之甚少。
描述美国中毒控制中心报告的拉科酰胺暴露情况，包括患者人口统计学特征、临床影响和结局。
本回顾性观察性研究通过国家毒物数据系统（NPDS）查询了 2008 年 1 月至 2016 年 12 月期间单一物质拉科酰胺暴露的情况。感兴趣的变量包括年龄、性别、医疗结局、管理地点、医疗保健机构级别、暴露原因和临床影响。
共确定了 1124 例拉科酰胺暴露患者，年龄从 2 个月至 99 岁。622 例（55.3%）为女性。976 例（86.8%）患者仅有轻微或无毒性作用。危及生命的暴露有 30 例（2.7%）。有 1 例死亡。548 例（48.8%）患者无需医疗管理，537 例（47.7%）被转至或已在医院。在接受医疗保健机构治疗的患者中，269 例（50.1%）无需住院。33 例（6.1%）患者被收治到精神病院，68 例（12.7%）收治到非重症监护病房，93 例（17.3%）收治到重症监护病房。632 例（56.2%）暴露是由于治疗性错误。自杀企图有 168 例（14.9%）。常见的症状包括神经、胃肠道和心血管症状。
拉科酰胺暴露很少导致死亡或残疾；然而，研究人群中有相当大的一部分需要重症监护。有症状的暴露患者需要进行医疗评估。
